Chemical formula: C₂₂H₂₇ClN₄O₃S Molecular mass: 462.149 g/mol
Abciximab is indicated for:
Population group: only adults (18 years old or older)
Abciximab is indicated as an adjunct to heparin and acetylsalicylic acid for the short-term (1-month) reduction of the risk of myocardial infarction, in patients with unstable angina, not responding to full conventional therapy who have been scheduled for percutaneous coronary intervention.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Population group: only adults (18 years old or older)
Abciximab is indicated as an adjunct to heparin and acetylsalicylic acid for the prevention of ischaemic cardiac complications in patients undergoing percutaneous coronary intervention (PCI: balloon angioplasty, atherectomy, and stent).
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Abciximab is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
